Company: PTHS
Filing Date: 2025-05-09
Form Type: PREM14C
Source: 0001140361-25-018219
Chunk: 97

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-09
Form: PREM14C
Chunk 97
---
>

TABLE OF CONTENTS

amount is paid to the holders of Channel common stock, in an amount in cash equal to the aggregate liquidation value of all of the shares of preferred stock held by such holder. Holders of the Channel Series C Preferred Stock will not be entitled to dividends. The payment of the liquidation preferences on the Channel Series C Preferred Stock could result in holders of Channel common stock not receiving any proceeds if Channel was to liquidate, dissolve or wind up, either voluntarily or involuntarily. The existence of the liquidation preferences may reduce the value of Channel common stock, make it harder for Channel to sell shares of Channel common stock in offerings in the future, or prevent or delay a change of control. If securities analysts do not publish research or reports about Channel’s business or if they publish negative evaluations of its stock, the price of Channel common stock could decline. The trading market for Channel common stock relies, in part, on the research and reports that industry or financial analysts publish about Channel or its business. If securities analysts do not commence coverage of Channel, the trading price of Channel common stock could decrease. Additionally, if one or more of the analysts covering Channel’s business downgrade their evaluations of Channel common stock, the price of Channel common stock could decline. If one or more of these analysts cease to cover Channel common stock, Channel could lose visibility in the market for Channel common stock, which in turn could cause the price of Channel common stock to decline. The price of Channel common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of Channel common stock. The market price of our securities is likely to be highly volatile due to many factors, including:

| • | Channel’s ability to successfully proceed to and conduct clinical trials; |

| • | results of pre-clinical and clinical trials of its existing lead or new future compounds or those of its competitors; |

| • | the success of competitive products or technologies; |

| • | commencement or termination of collaborations; |

| • | regulatory or legal developments in the United States and other countries; |

| • | developments or disputes concerning patent applications, issued patents or other proprietary rights; |

| • | the recruitment or departure of key personnel; |

| • | the level of expenses related to any of Channel’s current or future compounds or clinical development programs; |

| • | the results of its efforts to discover, develop, acquire or in-license additional new compounds; |

| • | actual or anticipated changes in estimates as to financial results